Note: Descriptions are shown in the official language in which they were submitted.
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
BLOOD GLUCOSE CONTROL SYSTEM
BACKGROUND
Standard-of-care insulin therapies for regulating blood glucose in diabetes
typically
involve either multiple daily subcutaneous injections or subcutaneous infusion
with an insulin
pump. In the case of the former, daily boluses of long-acting insulin
formulations, which
release slowly into the blood stream, are used to provide the subject's basal
metabolic insulin
requirement and boluses of rapid-acting insulin formulations, which absorb
rapidly into the
blood stream, are used to provide insulin for meals or to treat hyperglycemia.
In the case of
insulin pump therapy, either regular human recombinant insulin is used or,
more typically,
one of several rapid-acting insulin formulations is used to provide both basal
and bolus
therapy. In this case, a pre-programmed basal insulin infusion rate (or a
preprogrammed daily
"profile" containing several different basal insulin infusion rates that vary
throughout the day)
is prescribed and administered automatically by the insulin pump throughout
the day, and
individual boluses to insulin for meals or to treat hyperglycemia are
administered with the
insulin pump manually by the subject as needed. The preprogrammed basal
insulin infusion
rate (or pre-programmed daily basal insulin infusion rate profile) can be
changed to (or
temporarily overridden with) a different infusion rate by the subject, but
once implemented,
will execute the prescribed infusion rate without knowledge of, or regard to,
instantaneous
glucose levels from a continuous glucose monitoring device.
Clemens & Hough (US Patent 4,464,170) introduced the idea of using glucose-
sensor
data (obtained from a device capable of frequently sampling blood glucose
concentration
levels) to modulate the basal infusion rate relative to a previously
prescribed basal insulin
infusion rate during online operation of an autonomous glucose control system.
Their strategy
attempts to control drift in blood glucose away from a set point blood glucose
value by
considering the slope of the least squares fit to past blood glucose values.
The method is
described in the context of intravenous insulin infusion in an in-patient
setting and implicitly
assumes that insulin administered by the controller appears instantly in
blood.
SUMMARY
Techniques are disclosed for adaptation of certain drug-administration
parameters that
control insulin delivery in a blood glucose control system. In one aspect, a
technique
- 1 -
CA 02816314 2014-12-19
provides relatively long-term adaptation of a nominal basal infusion rate
around which the
infusion of basal insulin is automatically modulated. Use of the method can
provide not only
a daily control regime tailored to an individual patient, but one that can
also adapt to longer-
term changes in a patient's needs such as may arise from growth, illness,
hormonal
fluctuations, physical activity, aging, etc. In another aspect, another
technique provides
similar adaptation of the size of bolus insulin provided at mealtimes,
offering the potential of
overall better glycemic control in individuals and also providing the
adaptation to longer-term
changes in a patient's needs. Both techniques may employ adaptation
calculations using a
receding-horizon window of recent values of the adapted parameter. In yet
another aspect, the
system also delivers doses of a counter-regulatory agent such as glucagon to
the subject in
response, at least in part, to information about estimated accumulation of
exogenously infused
insulin (either subcutaneously, intramuscularly, intraperitoneally, or
intravenously) and/or the
effect that insulin might have on glucose levels (either blood glucose
concentration or
interstitial fluid glucose concentration).
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other objects, features and advantages will be apparent from
the
following description of particular embodiments of the invention, as
illustrated in the
accompanying drawings in which like reference characters refer to the same
parts throughout
the different views. The drawings are not necessarily to scale, emphasis
instead being placed
upon illustrating the principles of various embodiments of the invention.
Figure 1 is a block diagram of a blood glucose control system;
Figure 2 is a block diagram of a controller;
Figure 3 is a flow diagram of a first method of operation of the system;
Figures 4-5 are waveform diagrams depicting certain results of operation
according to
Figure 3; and
Figures 6-7 are flow diagrams of additional methods of operation of the
system.
DETAILED DESCRIPTION
- 2 -
CA 02816314 2014-12-19
Figure 1 illustrates an automated control system 10 for regulating the blood
glucose
level of an animal subject (subject) 12, which may be a human. The subject 12
receives doses
of insulin from one or more delivery devices 14, for example infusion pump(s)
coupled by
catheter(s) to a subcutaneous space of the subject 12. As described below, the
delivery
devices 14 may also deliver a counter-regulatory agent such as glucagon for
control of blood
glucose level under certain circumstances. For the delivery of both insulin
and glucagon, the
delivery devices 14 are preferably mechanically driven infusion mechanisms
having dual
cartridges for insulin and glucagon respectively. In the present description,
reference is made
to glucagon specifically, but it is to be understood that this is for
convenience only and that
other counter-regulatory agents may be used. Similarly, the term "insulin"
herein is to be
understood as encompassing all forms of insulin-like substances including
natural human or
animal insulin as well as synthetic insulin in any of a variety of forms
(commonly referred to
as an "insulin analogs").
A glucose sensor 16 is operatively coupled to the subject 12 to continually
sample a
glucose level of the subject 12. Sensing may be accomplished in a variety of
ways. A
controller 18 controls operation of the delivery device(s) 14 as a function of
a glucose level
signal 19 from the glucose sensor 16 and subject to programmed input
parameters
(PARAMS) 20 which may be provided by the patient/user. One feature of the
disclosed
technique is its ability to perform without receiving explicit information
regarding either
meals that the subject 12 has ingested or any other "feedforward" information.
One necessary
input parameter is the weight of the subject 12. Another externally provided
parameter is a
"setpoint" which, as described below, establishes a target blood glucose level
that the system
10 strives to maintain.
The controller 18 is an electrical device with control circuitry that provides
operating
functionality as described herein. In one embodiment, the controller 18 may be
realized as a
computerized device having computer instruction processing circuitry that
executes one or
more computer programs each including respective sets of computer
instructions. In this case
the processing circuitry will generally include one or more processors along
with memory and
input/output circuitry coupled to the processor(s), where the memory stores
computer
- 3 -
CA 02816314 2014-12-19
program instructions and data and the input/output circuitry provides
interface(s) to external
devices such as the glucose sensor 16 and delivery device(s) 14.
Figure 2 shows the structure of the controller 18. It includes four separate
controllers,
namely a glucagon controller 22, basal insulin controller 24, corrective
insulin controller 26.
and priming insulin controller 28. The basal insulin controller 24 includes a
nominal rate
controller 30 and a modulating controller 32. As shown, the glucagon
controller 22 generates
a glucagon dose control signal 34 provided to a glucagon delivery device 14-1.
Respective
outputs 36 - 40 from the controllers 24 -28 are combined to foun an overall
insulin dose
control signal 42 provided to insulin delivery device(s) 14-2. As shown, the
output signal 36
itself is formed by a combination of respective outputs of the nominal rate
controller 30 and
modulating controller 32. The insulin delivery device(s) 14-2 may include
devices tailored to
deliver different types and/or quantities of insulin, with the exact
configuration being known
to and under the control of the controllers 24 - 28. For ease of description
the collection of
one or more insulin delivery devices 14-2 is referred below to in the singular
as an insulin
delivery device 14-2.
Also shown in Figure 2 are input/output signals of the various controllers,
including
the glucose level signal 19 and parameters 20 as well as a set of inter-
controller signals 44.
The inter-controller signals 44 enable communication of information from one
controller,
where the information is developed or generated, to another controller where
the information
is used for that controller's control function. Details are provided in the
description of the
control functions below.
The corrective controller 26 regulates blood glucose level using an MPC cost
function
in a manner described in US patent publication 2008/0208113A1õ
Referring to the Clemens & Hough technique referred to above, while this
approach
may have practical utility in the setting of intravenous insulin infusion, it
is susceptible to
uncontrolled escalation of insulin dosing in an outpatient setting where
insulin infusion would
likely occur subcutaneously resulting in delayed absorption of insulin into
blood. Such an
approach would potentially have to be overridden often to limit escalation of
insulin dosing in
such a setting. Another limitation of the method is that it only captures one
time scale (equal
to the time associated with obtaining a fixed number of consecutive past
glucose levels); it
does not account for long-time variations in the subject's basal insulin
requirement.
- 4 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
Rather than relying solely on the previously prescribed basal insulin infusion
rate,
which is particularly vulnerable to a run-away escalation of insulin dosing
whenever
subcutaneous insulin administration is used, an alternative method (herein
referred to as
Method 1) modulates the basal insulin infusion rate around a fixed "nominal"
basal infusion
rate, which is determined prior to initiating online operation of the glucose
control system
(e.g. based on the subject's weight or based on previous open- or closed-loop
control results
in the subject). This can be described as follows: Through any manner by which
automated
insulin infusion may be controlled online (such as through a model predictive
control
strategy, a proportional-integral-derivative control strategy, fuzzy logic,
neural networks, or
some other control strategy), there can be added a basal infusion rate of
insulin delivered
when control or corrective doses of insulin are not otherwise indicated. Basal-
rate infusion
typically uses smaller but more frequent doses than priming or control doses
used to treat
meals or hyperglycemic excursions in glucose concentration levels. A fixed
nominal basal
infusion rate can be initially prescribed (i.e. just before initiating online
operation of closed-
loop control) and then modulated by its own control algorithm, or it can be
prescribed in
advance in the form of a fixed basal infusion rate profile that follows the
same pattern from
day to day (or week to week), and is then modulated online. The basal insulin
infusion rate is
automatically modulated around the fixed nominal infusion rate using any of a
variety of
control strategies including, but not limited to, model predictive control,
proportional-
integral-derivative control, fuzzy logic, neural networks, etc.
As another distinction from the method described by Clemens & Hough, the
modulation of the basal insulin infusion rate described here should be
constrained to fall
within minimum and maximum values around the nominal basal infusion rate so as
to prevent
a run-away escalation of insulin dosing. The maximum value may be, for
example, some
constant multiple of the fixed nominal basal infusion rate.
Although Method 1 represents an improvement upon the technique of Clemens &
Hough by preventing runaway escalation of insulin dosing through constraining
the maximum
instantaneous basal infusion rate, it only captures one time scale, i.e. that
which is associated
with the sampling interval between glucose measurements. Method 1 can be
further improved
with an alternative method (herein referred to as Method 2) that allows the
nominal basal
infusion rate itself to vary over time, which, in turn, allows the
instantaneous basal infusion
rate to inherit a second longer time scale capable of capturing physiological
variations in the
- 5 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
subject's basal metabolic insulin requirement. Whereas the instantaneous basal
infusion rate
can change rapidly on the very short time scale associated with the sampling
interval between
glucose measurements, the introduction of a nominal basal infusion rate that
varies over time
more slowly than the instantaneous basal infusion rate provides a second
degree of freedom
that can capture physiological drift in a subject's basal metabolic insulin
requirement while
still constraining the maximum instantaneous basal infusion rate to be some
constant multiple
of the nominal basal infusion rate, and thereby preventing run-away escalation
of basal
insulin dosing.
In particular, referring to Figure 3, the basal insulin controller 24
generates the insulin
dose control signal 42 via its output signal 36 in response to the glucose
level signal 19. At
46, the controller 24 modulates a basal infusion rate of insulin about a
nominal basal infusion
rate in response to short-term variations of glucose level occurring on the
order of seconds to
minutes (referred to as a "sampling interval" below). At 48, the controller 24
continually
adjusts the nominal basal infusion rate based on a mathematical relationship
between the
basal infusion rate as modulated and the nominal basal infusion rate over a
longer term than a
short term (e.g., sampling interval) associated with modulating the basal
infusion rate.
As an example of one embodiment of Method 2, the nominal basal infusion rate
of
insulin (or an insulin-like agent) can be initially prescribed at t = 0 as
1u0. Then, the nominal
basal infusion rate, tit(t), can begin being calculated online (and updated at
each sampling
interval, St) as a scalar multiple of the moving integral average value of the
instantaneous
basal infusion rate, p(t) 0, over the time interval, At, such that
It@ + St) = ¨a p(r)dr, At
(1)
At t At
where a is a scaling parameter. Alternatively, the implementation could be
performed in
discrete time, where k is the index of the current time step, St is the size
of the discrete time
step (i.e. an index increment of 1), and N = At I St is the size of the time
interval, giving the
alternative form for the instantaneous dynamic nominal basal infusion rate of:
a
kN
(2)
lik+1 7
J=k-N
The instantaneous basal infusion rate, p(t), or pk in discrete time, is
allowed to
modulate around the instantaneous dynamic nominal value, Tt(t), or Tik in
discrete time.
- 6 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
Specifically, p(t) (or pk) can be increased or decreased when the glucose
level rises or falls
below a set-point glucose value or a set range of glucose values. Modulation
of p(t) around
Ti(t) (or pk around Tik ) can also be affected by the rate of increase or
decrease of the glucose
level. More sophisticated control methods could also be employed to determine
the
modulation of p(t) around Ti(t) (or pk around Tik ), such as, but not limited
to, using a model
predictive control strategy, a proportional-integral-derivative control
strategy, fuzzy logic,
neural networks, or some other control strategy.
Figures 4 and 5 provide an illustration of the effect of the method of Figure
3. Figure 4
shows a modulated basal infusion rate 49 about a fixed constant nominal basal
infusion rate
51. Figure 5 shows a modulated basal infusion rate 49' about a continually
adapted nominal
basal infusion rate 51'.
Thus, Method 2 offers an approach that is capable of both preventing run-away
escalation of insulin dosing (by constraining the maximum instantaneous basal
infusion rate
to be some constant multiple of the dynamic nominal basal infusion rate) as
well as capturing
multiple time scales for adaptation. In particular, p(t) (or pk) is allowed to
vary rapidly
online over a time scale St (which might be on the order of minutes in real
time and 0(1) in
discrete time), whereas Ti(t) (or Tik ) around which p(t) (or pk) modulates,
varies more
slowly online over a time scale At (which might be on the order of hours in
real time and
0(N) in discrete time).
The approach according to Method 2 sets the instantaneous dynamic nominal
basal
infusion rate, Ti(t) (or Tik ), equal to a constant multiple of the average
nominal value over
some receding time interval, At (or N). In an alternative embodiment (herein
referred to as
Method 3), the instantaneous dynamic nominal basal infusion rate can be
adapted online so as
to enforce a constant ratio over the interval At (or N) between all of the
modulated
instantaneous basal infusion rates, p(t) (or pk), and their corresponding
moving average
dynamic nominal basal infusion rates, Ti(t) (or Tik ). In other words, to
enforce such a
constant ratio of fl , then
II(t + St) = Ti(t) I= f 111¶ - _______________ 1 dr, , t At
(3)
\ At
or in discrete time,
- 7 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
if)
L 5 k N
(4)
J=k-N
In the same manner as described above for Method 2, in Method 3, the
instantaneous
basal infusion rate, ,u(t) (or ,uk ), is allowed to modulate around the
instantaneous dynamic
nominal value, ,it(t) (or ,itk in discrete time).
In either implementation, i.e. according to either Method 2 (Equations (1) and
(2)) or
Method 3 (Equations (3) and (4)), the determined dynamic nominal basal
infusion rate can be
limited between a global minimum value, 5
and a global maximum value, T I, 5 i.e.
T I, in Equations (1) and (3) or Tik in
Equations (2) and (4). The
implementation of Method 2 or Method 3 described above could also start taking
effect
gradually online (e.g. linearly) from t= 0 (or k= 0) until the interval size,
At (or N), is
reached online.
Methods 2 or 3 can equally be applied to adapt online a nominal basal-rate
profile that
includes a set of different nominal basal-rate levels that could be prescribed
for different time
periods of the day or for different days, or both. The individual nominal
basal-rate levels
within a (daily or semi-daily) profile could be of different time durations
and their durations
or their starting and ending times could also vary from day to day. The
individual nominal
basal-rate levels could be prescribed globally for all individuals or could be
prescribed
differently for different individuals, and could be based on previous control
results (e.g. open-
loop or closed-loop settings for each individual subject).
An example of this embodiment is to use the method above to adapt an initially
prescribed ,t10:= ,ii (t) (or pok in discrete time) that could be represented
as a piecewise
function. As such, Equations (1) or (3) in real time (or Equations (2) and (4)
in discrete time)
could be applied to each of the individual nominal basal-rate levels within
the piecewise
function. At the time juncture between consecutive nominal basal-rate levels,
the transition
could occur as a discontinuous jump from the nominal basal-rate level of the
elapsed time
period to the nominal basal-rate level of the entered time period.
Alternatively, the transition
could occur in a gradual fashion (e.g. linearly) over a certain time period
that could be fixed
or variable. Moreover, the previous adaptation history of individual nominal
basal-rate levels
could be inherited upon subsequently encountering the same or an overlapping
time period or
- 8 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
time juncture (e.g. on the next day or after a number of days). The online
instantaneous basal
infusion rate could then be a modulation based on the current nominal basal-
rate level
pertaining to the current time period online, or based on adjacent nominal
basal-rate levels
during a transition between nominal basal-rate levels online.
All of the methods described above could be used in the in-patient (e.g.
critical care
units or general wards) or out-patient settings and could be used in the
context of an
autonomous or semi-autonomous closed-loop blood-glucose control system. The
methods
could also be used in open-loop systems where only the basal infusion rate is
automatically
controlled and all other doses are manually administered. In any case,
modulation of the
instantaneous basal infusion rate, ,u(t) (or ,uk ), and long-time adaptation
of those
modulations around the moving average dynamic nominal basal infusion rate,
Tt(t) (or ,k)'
will involve a sensor-augmented infusion system that is capable of responding
to frequent
(typically every 5-15 minutes) glucose measurements from a continuous glucose
monitor or
other glucose measuring device. Another utility involves utilizing the basal
infusion rates
obtained with any of these methods online in a sensor-augmented infusion
system to inform
open-loop basal-rate profile settings that could be prescribed for the subject
when the system
is (temporarily or permanently) not driven by the glucose sensor, such as
during periods of
temporary interruptions or dropouts in the glucose sensor signal, or for open-
loop insulin
infusion therapy.
In another aspect, a method is shown for automatically adapting doses of
infused
insulin or insulin-like agents (either subcutaneously, intramuscularly,
intraperitoneally, or
intravenously) where the doses are intended to partially or fully compensate
for food
(carbohydrate) consumption. The doses can be administered prior to, during, or
after food
consumption, or could be split across these times. The online adaptation
method can
automatically tune these meal-time insulin doses on an individual basis and
can automatically
adjust them over time to respond to long-time changes in the individual's
insulin requirement,
such as might occur over a period of weeks, months, or years due to
developmental changes
(e.g. due to hormonal changes that occur during puberty or menopause), or as
might occur
over a period of hours, days, or weeks due to transient changes (e.g. due to
circadian
hormonal fluctuations, intercurrent illness, physical activity, or emotional
state).
Standard-of-care insulin therapies for regulating blood glucose in diabetes
typically
involve either multiple daily subcutaneous injections or subcutaneous infusion
with an insulin
- 9 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
pump. Typically, combinations of "basal and bolus" insulin are administered to
meet the
subject's basal metabolic insulin requirement as well to regulate
hyperglycemia; additional
"meal bolus" doses (also referred to herein as "priming doses") are added to
provide insulin
for food consumption. Insulin doses intended to compensate for meals are
usually estimated
on an individual basis based on the quantity and content (carbohydrate and
other) of the food,
in conjunction with an estimate of the individual's so-called "insulin-to-
carbohydrate ratio",
among other factors such as the time of the day, physical activity, health
state, emotional
state, etc. The correct meal-bolus insulin amount, therefore, could vary
significantly among
individuals as well as within an individual. Moreover, the amount of meal-
bolus insulin is
often a major determinant of how well an individual is able to control their
blood glucose. We
provide a method that would automatically and continually adjust meal-time
doses of insulin
(intended to partially or fully compensate for food consumption), based on the
individual's
response to previous meal doses.
In particular, referring to Figure 6, at 50 the priming insulin controller 28
continually
administers priming doses of insulin at respective times, each priming dose
being of a
respective amount and having a prescribed interval of action. At 52, the
controller 28 receives
information (e.g., from the other controllers 24-26 via signals 44) regarding
total amounts of
insulin administered during the prescribed intervals of action, each total
amount including an
aggregation of total doses administered in response to a glucose level signal.
At 54, the
controller 28 automatically adapts the amounts of the priming doses in
response to a
mathematical relationship, over respective periods each spanning multiple
prescribed
intervals of action, between the amounts of the priming doses and the total
amounts of insulin
administered during the prescribed intervals of action.
As an example of one embodiment of the method of Figure 6, the effective
instantaneous dynamic meal-time bolus (which can be split into a number of
doses), Bin (t)
(or /3/7in discrete time), corresponding to meal m (or corresponding to a time
interval m) on
any given day t (or k in discrete time), can be adapted online so as to
enforce, on average,
over a time horizon of At (or N in discrete time) days (e.g. 1 week or 1 month
long) a certain
target ratio, flm , between the magnitudes of Bin (t) (or /3/7) and their
corresponding overall
insulin amount around that meal (or time interval), Pm (t) (or Pkm ), where
Pm (t) = Bin (t)+ Cm (t) (or Pk"' = /3/7 + C km ) , where Cm (t) (or C/7 )
includes all prandial and
- 10 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
post-prandial insulin (other than Bin (t) (or Br)) that was given by the
control system for that
meal (or corresponding to time interval) m, computed over a certain prandial
and post-
prandial time interval of St hours (e.g. 5 hours). In other words, to enforce
(on average) a
ratio flm (e.g. 50-75%) between Bin (t) and overall dosing Pm (t) around meal
(or time
interval) m on day t + 1, then
t
Bin (r)
Bin (t +1) = flm Bin (t) 1 _________________________ dr , t At
(5)
At Bin (r)+ Cm (r)
t-At
or in discrete time,
\-1
1 k 13"1
Bkm+i= flmBkm - E __________________________________ k N
(6)
N Bm + Cm
j=k-N+1 )
The target ratios, fim , can also be varied over time, i.e. flm := flm (t) (or
fir).
Moreover, different time intervals St could be used in the computations of Cm
(r) (or C7) for
different meals m (or different time intervals m) of the day. Furthermore, the
implementation
could start taking effect gradually online (e.g. linearly or stepwise) from
the first
day at t = 1 (or k = 1) until the interval size At (or N) is reached online.
Alternatively, the
method can take its full effect from the start while transiently using n = 1,
2, 3,. . . in lieu of
the intended full interval size N, until n reaches N, after which the
implementation takes on its
steady form of a "moving average" over its full "receding horizon" N. Finally,
the interval
length At (or N) could also be made variable with m and/or time t (or k).
The method described above could be used in the in-patient (e.g. critical care
units or
general wards) or out-patient settings and could be used in the context of an
autonomous or
semi-autonomous closed-loop blood-glucose control system. Feedback from the
use of this
method during autonomous or semi-autonomous control could also be used to
inform open-
loop systems, that may or may not be augmented with an online glucose sensor.
In another aspect, a method is shown for automatically modulating doses of
infused
glucagon (either subcutaneously, intramuscularly, intraperitoneally, or
intravenously) that
relies in part on information about the estimated accumulation of exogenously
infused insulin
(either subcutaneously, intramuscularly, intraperitoneally, or intravenously)
and/or the effect
that insulin might have on glucose levels (either blood glucose concentration
or interstitial
- 11 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
fluid glucose concentration). Through any manner by which automated glucagon
infusion
may be controlled online (such as through a model predictive control strategy,
a proportional-
derivative control strategy, or some other control strategy), there can be
derived a
mathematical formulation by which the control dose of glucagon depends in some
manner
upon the estimated accumulation of exogenously infused insulin. Specifically,
the particular
formulation employed would cause the glucagon infusion rate (or delivery
amount) to be
higher at times when the accumulation of infused insulin is relatively higher
than it would be
at times when the accumulation of infused insulin is relatively lower.
In particular, referring to Figure 7, at 56 the glucagon controller 24
generates the
counter-regulatory agent dose control signal 34 by performing a calculation
generating (1) a
raw dose control value based on the glucose level signal, and at 58 generating
(2) the counter-
regulatory agent dose control signal as a modification of the raw dose control
value based on
an estimation of an effect of the exogenously infused insulin.
As an example of one embodiment of the method of Figure 7, glucagon could be
controlled with using a proportional-derivative (PD) control strategy where
the control doses
thus determined would be scaled using a multiplying factor that is
proportional to (either
linearly or nonlinearly) the estimated accumulation of exogenously infused
insulin. Whenever
the glucose concentration falls below some set point, or whenever the glucose
concentration
falls below some threshold value, 16 , with a sufficiently rapid descent, a
glucagon dose,
Gdose (t), might be triggered as follows:
Gdose = f e(t)) {kp(t6 Yt) kd(Yt-1¨ Yt)1 Ts); 0 Gdose(t) Gmax
(7)
where G., is the maximum allowable glucagon dose (which may be infinite), t is
in discrete
time, k is the proportional gain, kd is the derivative gain, Ts is the
sampling period, ie(t) is the
estimated accumulation of exogenously infused insulin, and f(ie(t)) is some
specified function
of ie(t) that has units of Gdose(t). An examplef(ie(t)) might be a sigmoidal
function that is near
unity whenever ie(t) is less than some factor times some estimated nominal or
baseline value
of the plasma insulin level and then begins to increase significantly as ie(t)
exceeds this
nominal value. Alternatively, in another embodiment, the dependence of Gdose
(t) on
might appear in an additive way, by the introduction of an additional gain
parameter, ki, such
that
Gdose = k (fl Yt)+ka (Yt_1¨ yt)1 Ts k e(t); 0 Gdose(t) Gm,
(8)
- 12 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
where ki might vanish whenever ie(t) is less than some factor times some
estimated nominal
or baseline value of the plasma insulin level.
Variations on the above examples might include an additive term, Gp
ending (t) , which is
deducted from Gdõe(t) 5 and which represents an estimate of pending
subcutaneous glucagon
from recent doses. This could be computed, for example, with a function such
as
90/T,kT G
1 112
G Pending (0 ¨ I Gdose(t t_)
(9)
k=1
where G112 is an estimate of the average half life of subcutaneous doses of
glucagon. Note that
the estimate Gpending (t) limits unnecessary subcutaneous accumulation of
glucagon. Thus,
including G pending (t) in Equations (7) and (8) could provide the alternate
forms given by
G dose (0 = f e(t)){k p ()a t) kd (Yt-1¨ Y t) 1 Ts ¨ G pending (t)} ; o
Gdose(t) G (10)
G X 5
Gdose(t) = k p (fl Yt) kd(Yt-1¨ Yt)I Ts kd G pending (0; Gdose(t)
( 1 1 )
Alternatively, G pending (t) might appear in an additive way, by the
introduction of an additional
gain parameter, kg, such that G pending in Equations (10) and (11) might be
replaced by
kgge(t), where ge(t) is the estimated accumulation of exogenously infused
glucagon.
In yet another embodiment, the control doses of glucagon, Gdose(t) 5 may
employ a
model predictive control (MPC) strategy, where the modulation of glucagon
doses due to the
estimated accumulation of exogenously infused insulin, ie(t), could be
achieved using an outer
scaling function (similar to the functionf(ie(t)) in Equation (7)). For
example, the control
doses of glucagon may be computed as:
Gdose(t) = g(ie(t))ut; 0 Gdose(t) Gmax 5
(12)
where ut is the MPC glucagon dose signal and g(ie(t)) is an outer scaling that
is similar or
identical tof(ie(t)) in that it is some function that is near unity whenever
ie(t) is less than some
factor times some estimated nominal or baseline value of the plasma insulin
level and is
significantly higher when as ie(t) exceeds this nominal value. One example for
computing ut
is using an MPC cost function such as:
- 13 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
2 N'
I sklIc(rt+k -yt,k)11 I ilk(AUt+02
(13)
k=Na k=0
where ut denotes the MPC glucagon dose signal, yt the glucose concentration
signal, rt the
reference set point signal, Nd and Nõ., are respectively the minimum and
maximum (output)
prediction costing horizon limits, Nu the control horizon bound, m the
weighting on prediction
error, and 2, the weighting on control signals. The glucose concentration, yt,
and the glucagon
dose signal, ut, could also be related by subject model. Upon solving Equation
(13) for the
MPC glucagon dose signal, ut, the outer scaling with g(ie(t)) could then be
applied as per
Equation (12) to compute the control doses of glucagon, Gdõe(t) .
Alternatively, the control
doses of glucagon, Gdõe(t) 5 could be based on the MPC glucagon dose signal,
ut, and an
incorporation of the effect of ie(t) in an additive way, by the introduction
of a gain parameter,
ki, such that
Gdose(t) = ut kite )t); 0 Gdose(t) Gmax 5
(14)
where ki might vanish whenever ie(t) is less than some factor times some
estimated nominal
or baseline value of the plasma insulin level.
Furthermore, the control doses of glucagon, Gdose (t), could also take into
account the
accumulation of glucagon from past glucagon doses. This could be handled by
computing a
quantity Gpending (t) similar to that described in Equation (9) and computing
the control doses
of glucagon as per
Gdose (t) = g(ie(t)){tit ¨ G pending (t)} ; 0 Gdose(t) Gmax 5
(15)
or
+ ki(ie(t)) Gdose(t) G X 5
(16)
Gdose(t)= ut G pending (t); 0
Alternatively, Gpending (t) might appear in an additive way, by the
introduction of an additional
gain parameter, kg, such that Gpending (t) in Equations (15) and (16) might be
replaced by
kgge(t), where ge(t) is the estimated accumulation of exogenously infused
glucagon.
Another option for accounting for the accumulation of glucagon from past doses
is by
augmenting the MPC cost function in Equation (13) with a mathematical
formulation that
- 14 -
CA 02816314 2013-04-26
WO 2012/058694
PCT/US2011/058688
estimates the accumulation of exogenous glucagon in a manner similar to that
described in
US patent publication 2008/0208113A1. Such an augmentation could take into
account the
accumulation of glucagon in both the administration site(s) as well as in
plasma and could be
based on pharmacokinetics of the administered glucagon pertaining to the
method or route of
administration as well as to the specific constituents present in the glucagon
solution,
including the type of glucagon or glucagon analog itself With such an
augmentation in effect,
the MPC glucagon dose signal, ut, becomes an augmented MPC glucagon dose
signal, ,dt .
The augmented MPC glucagon dose signal, it:, could replace the MPC glucagon
dose signal,
in both Equations (12) and (14) to provide the control doses of glucagon, G
dose(t) .
Other control signals could replace the MPC glucagon dose signal, ut, in
Equations
(12), (14), (15), or (16) and could be based on another algorithm such as a
neural network, or
a fuzzy logic, or a standard optimization algorithm.
In all the formulations above, the function ie(t) may be computed by any
manner by
which the accumulation of exogenously infused insulin might be estimated.
It will be appreciated that the present invention may be embodied as an
overall system
such as shown in Figure 1, as an overall method, as a controller such as shown
in Figure 2,
and as methods performed by a controller such as shown in Figures 3-5. With
respect to the
methods performed by a controller, the methods may be performed by computer
program
instructions executed by generic controller hardware including memory, a
processing or
execution unit, and input/output circuitry. The instructions may be provided
to the controller
from a computer-readable medium such as semiconductor memory, magnetic memory
(e.g.
magnetic disk), optical memory (e.g. optical disk such as CD, DVD), etc.
While various embodiments of the invention have been particularly shown and
described, it will be understood by those skilled in the art that various
changes in form and
details may be made therein without departing from the scope of the invention
as defined by
the appended claims.
- 15 -
